Ovarian Cancer Clinical Trials


Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Bendamustine HCL
Sponsors:   University of Arizona;   Cephalon
Completed - verified December 2015

Learn More

A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Paclitaxel, Carboplatin and Vorinostat
Sponsors:   Herlev Hospital;   Odense University Hospital
Unknown status - verified October 2008

Learn More

NYU Ovarian Cancer Early Detection Program Blood and Genetics

Condition:   Ovarian Cancer
Intervention:  
Sponsor:   New York University School of Medicine
Terminated - verified January 2011

Learn More

Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function

Condition:   Ovarian Cancer
Intervention:   Behavioral: Fertility-Sparing Survey
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Massachusetts General Hospital
Completed - verified November 2016

Learn More

Elizabeth Registry for Low Grade Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Completed - verified October 2015

Learn More

Weekly Topotecan Therapy in Patients With Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Topotecan
Sponsor:   Weill Medical College of Cornell University
Terminated - verified September 2006

Learn More

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Imatinib Mesylate;   Drug: Docetaxel
Sponsors:   Daniela Matei, MD;   Novartis Pharmaceuticals;   Sanofi;   Walther Cancer Institute
Completed - verified February 2016

Learn More

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Conditions:   Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions:   Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
Sponsors:   Northwestern University;   National Cancer Institute (NCI)
Recruiting - verified September 2016

Learn More

Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling

Condition:   Breast Cancer
Intervention:   Behavioral: Self Affirmation
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified July 14, 2017

Learn More

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers

Conditions:   Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Breast Ductal Carcinoma NOS;   Melanoma;   Solid Tumors Cancer of Unknown Primary;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma;   Pancreatic Neoplasms;   Ovarian Neoplasms;   Carcinoma, Renal Cell;   Cholangiocarcinoma;   Skin Carcinoma;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms, Nerve Tissue;   Nevi and Melanomas;   Intestinal Neoplasms;   Thyroid Cancer;   GIST;   Malignant Peripheral Nerve Sheath Tumors;   Breast Secretory Carcinoma;   Uterine Neoplasms
Intervention:   Drug: LOXO-195
Sponsor:   Loxo Oncology, Inc.
Recruiting - verified July 2017

Learn More

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Conditions:   Cancer of Ovary;   Neoplasms, Ovarian;   Ovarian Cancer Stage IV;   Ovarian Cancer Recurrent;   Ovarian Cancer Stage III;   Ovary Cancer
Interventions:   Biological: Oregovomab;   Drug: Poly ICLC
Sponsor:   OncoQuest Inc.
Recruiting - verified July 2017

Learn More

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Conditions:   Solid Tumor, Adult;   Breast Cancer;   Non Small Cell Lung Cancer;   Prostate Cancer;   Ovarian Cancer;   Endometrial Cancer;   Head and Neck Cancer;   Cholangiocarcinoma
Intervention:   Drug: CX-2009
Sponsor:   CytomX Therapeutics
Recruiting - verified July 2017

Learn More

A Study of SC?004 in Subjects With Advanced Solid Tumors

Condition:   Advanced Solid Tumor Cancers
Intervention:   Drug: SC-004
Sponsor:   AbbVie
Recruiting - verified July 2017

Learn More

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Conditions:   Advanced Malignancies;   Metastatic Malignancies
Interventions:   Drug: INCAGN01876;   Drug: Nivolumab;   Drug: Ipilimumab
Sponsor:   Incyte Biosciences International Sàrl
Recruiting - verified July 2017

Learn More

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Condition:   Advanced or Metastatic Solid Tumors
Interventions:   Drug: ABBV-368;   Drug: Nivolumab
Sponsor:   AbbVie
Recruiting - verified July 2017

Learn More

16-30 of 69
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.